Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients.
In patients from two clinical trials, we investigated the associations of single nucleotide polymorphisms (SNPs) in candidate genes with prolactin level changes during treatment with olanzapine/fluoxetine combination. In both cohorts, three dopamine receptor D2 (DRD2) SNPs were associated with prolactin changes. DRD2 may influence susceptibility to hyperprolactinemia associated with antipsychotic treatment.
Houston
John P
JP
Lilly USA, LLC, Indianapolis, IN 46285, USA. houston_john_p@lilly.com
Fijal
Bonnie
B
Heinloth
Alexandra N
AN
Adams
David H
DH
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D003863:Depression / Q000188:drug therapy / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects*; D055106:Genome-Wide Association Study / Q000379:methods; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011388:Prolactin / Q000097:blood*; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D044465:White People; D055815:Young Adult
D014150:Antipsychotic Agents; D004338:Drug Combinations; D017448:Receptors, Dopamine D2; C492572:olanzapine-fluoxetine combination; D005473:Fluoxetine; D001569:Benzodiazepines; D011388:Prolactin